For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?

This is rare but I've seen it twice last year! One with melanoma on nivolumab and one with lung cancer on pembrolizumab (both cases in deep remission), both with difficult-to-control multiple myeloma who qualify for a bispecific antibody like teclistamab. Would you be willing to use PD-1 inhibition and BCMAxCD3 targeting together?